Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Introduction and rollout of a new group a meningococcal conjugate vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014
Clinical Infectious Diseases, Volume 61, Year 2015
Notification
URL copied to clipboard!
Description
Background. A group A meningococcal conjugate vaccine (PsA-TT) was developed specifically for the African "meningitis belt" and was prequalified by the World Health Organization (WHO) in June 2010. The vaccine was first used widely in Burkina Faso, Mali, and Niger in December 2010 with great success. The remaining 23 meningitis belt countries wished to use this new vaccine. Methods. With the help of African countries, WHO developed a prioritization scheme and used or adapted existing immunization guidelines to mount PsA-TT vaccination campaigns. Vaccine requirements were harmonized with the Serum Institute of India, Ltd. Results. Burkina Faso was the first country to fully immunize its 1- to 29-year-old population in December 2010. Over the next 4 years, vaccine coverage was extended to 217 million Africans living in 15 meningitis belt countries. Conclusions. The new group A meningococcal conjugate vaccine was well received, with country coverage rates ranging from 85% to 95%. The rollout proceeded smoothly because countries at highest risk were immunized first while attention was paid to geographic contiguity to maximize herd protection. Community participation was exemplary. © 2015 World Health Organization; licensee Oxford Journals.
Authors & Co-Authors
Djingarey, Mamoudou Harouna
Switzerland, Geneva
Organisation Mondiale de la Santé
Diomandé, Fabien V.K.
United States, Atlanta
Centers for Disease Control and Prevention
Barry, Rodrigue
Switzerland, Geneva
Organisation Mondiale de la Santé
Kandolo, Denis
Switzerland, Geneva
Organisation Mondiale de la Santé
Shirehwa, Florence
Switzerland, Geneva
Organisation Mondiale de la Santé
Lingani, Clément
Switzerland, Geneva
Organisation Mondiale de la Santé
Novak, Ryan T.
United States, Atlanta
Centers for Disease Control and Prevention
Tevi-Benissan, Carol
Congo, Brazzaville
World Health Organization Regional Office for Africa Congo
Perea, William A.
Switzerland, Geneva
Organisation Mondiale de la Santé
Préziosi, Marie Pierre
Switzerland, Geneva
Organisation Mondiale de la Santé
France, Ferney-voltaire
Path
la Force, F. Marc
France, Ferney-voltaire
Path
India, Pune
Serum Institute of India Ltd.
Statistics
Citations: 45
Authors: 11
Affiliations: 5
Identifiers
Doi:
10.1093/cid/civ551
ISSN:
10584838
Research Areas
Health System And Policy
Maternal And Child Health
Study Design
Cross Sectional Study
Study Locations
Burkina Faso
Mali
Niger